Latest News for QNTM
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported its financial and operational results for the second quarter of 2026, ended June 30, 2026.
Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination Lucid-MS Advances Novel Disease-Modifying Approach Targeting Multi-Billion Dollar Progressive MS Market with Significant Unmet Medical Need Worldwide TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:…
Quantum Biopharma (NASDAQ: QNTM - Get Free Report) is anticipated to announce its results before the market opens on Thursday, August 6th. Analysts expect Quantum Biopharma to announce earnings of ($0.4116) per share for the quarter. Quantum Biopharma Stock Down 5.9% NASDAQ QNTM opened at $2.87 on Wednesday. The firm has a market cap of $18.37
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for QNTM.
Senate Trading
No Senate trades found for QNTM.
U.S. House Trading
No House trades found for QNTM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.